J.S. Ahn

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy

Seung Hwan Moon, Su-Hee Cho, Lee Chun Park et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 60 citations

Medicine, Nuclear Medicine, Oncology +17

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Fabrice Barlési, Anne‐Marie C. Dingemans, James Chih‐Hsin Yang et al. · Annals of Oncology · 2016 · 14 citations · Full text

Medicine, Oncology, Pharmacology +14

Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma: Similar to that for Small Cell Lung Cancer or Non-Small Cell Lung Cancer?

Jinping Sun, M-J. Ahn, J.S. Ahn et al. · Annals of Oncology · 2012 · 12 citations · Full text

Medicine, Oncology, Chemotherapy +15

3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)

Fabrice Barlési, Anne‐Marie C. Dingemans, I. Ou et al. · European Journal of Cancer · 2015 · 11 citations

Medicine, Oncology, Pharmacology +16